Trial reportThe Journal of clinical endocrinology and metabolism2006
Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
Trial report in The Journal of clinical endocrinology and metabolism, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00246402 (Anti-Lipolytic Strategy for HIV Lipodystrophy), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-Lipolytic Strategy for HIV Lipodystrophy
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.The Journal of clinical endocrinology and metabolism · 2016Trial
- Targeting fat browning in hypermetabolic conditions: a clinical perspective.Future science OA · 2020Article
- Adipose Tissue Metabolic Function and Dysfunction: Impact of Burn Injury.Frontiers in cell and developmental biology · 2020Review
- Article
- Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.World journal of virology · 2015Review
- Treatment of dyslipidemia in HIV.Current atherosclerosis reports · 2015Review
- Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Endocrine · 2012Review
- Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.The American journal of clinical nutrition · 2011Review
- Therapy: HIV-associated dyslipidemia: the heart positive study.Nature reviews. Endocrinology · 2011Article
- Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.Metabolism: clinical and experimental · 2011Article
- Lipodystrophy: pathophysiology and advances in treatment.Nature reviews. Endocrinology · 2011Review
- Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.Arteriosclerosis, thrombosis, and vascular biology · 2009Article
- Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.British journal of pharmacology · 2009Review
- Relationship of postprandial nonesterified fatty acids, adipokines, and insulin across gender in human immunodeficiency virus-positive patients undergoing highly active antiretroviral therapy.Metabolic syndrome and related disorders · 2009Article
- HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms.AIDS research and therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
contextMetabolic abnormalities such as hypertriglyceridemia remain a challenge for optimizing long-term health in HIV-infected patients.
objectiveElevation of free fatty acids (FFAs) may contribute to hyperlipidemia and insulin resistance in HIV. We evaluated the efficacy and safety of chronic inhibition of lipolysis in HIV-infected men and women with hypertrigyceridemia. We hypothesized that acipimox would lead to significant reductions in triglycerides and improved insulin sensitivity, compared with placebo.
designA 3-month, randomized, double-blind, controlled trial of acipimox (250 mg thrice daily) vs. placebo was conducted in 23 HIV-infected men and women with hypertriglyceridemia (>150 mg/dl), abnormal fat distribution, and no current lipid-lowering therapy. The primary outcome variable was triglyceride concentration, and insulin sensitivity measured by hyperinsulinemic euglycemic clamp was a secondary outcome.
settingThe study was conducted at an academic medical center.
resultsAcipimox resulted in significant reductions in FFAs [mean change -0.38 (0.06) vs. 0.08 (0.06) mEq/liter with placebo, -68 vs. +17% change from mean baseline, P < 0.0001], decreased rates of lipolysis (P < 0.0001), and a median triglyceride decrease from 238 mg/dl at baseline to 190 mg/dl, compared with an increase from 290 to 348 mg/dl in the placebo group (P = 0.01). Acipimox improved insulin sensitivity [acipimox +2.31 (0.74) vs. placebo -0.21 (0.90) mg glucose per kilogram lean body mass per minute, or +31 vs. -2% change from mean baseline values, P = 0.04]. Improvements in insulin sensitivity were significantly correlated with reductions in FFAs (r = -0.62, P = 0.003) and lipolysis (r = -0.59, P = 0.005).
conclusionsAcipimox resulted in significant sustained reductions in lipolysis, improved glucose homeostasis, and significant but modest reductions in triglycerides in HIV-infected individuals with abnormal fat distribution and hypertriglyceridemia. Improvement in overall metabolic profile with acipimox suggests a potential clinical utility for this agent that requires further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.